Your data on MRCVSonline
The nature of the services provided by Vision Media means that we might obtain certain information about you.
Please read our Data Protection and Privacy Policy for details.

In addition, (with your consent) some parts of our website may store a 'cookie' in your browser for the purposes of
functionality or performance monitoring.
Click here to manage your settings.
If you would like to forward this story on to a friend, simply fill in the form below and click send.

Your friend's email:
Your email:
Your name:
 
 
Send Cancel

Gene therapy ‘can cure lameness’ - study
The research team believe this gene therapy could offer a much faster healing time.
Research may also have implications for human medicine 

A ‘promising’ gene therapy could offer faster and more effective treatment for lameness in horses, scientists say.

An international team injected DNA into the tendons and ligaments of horses that were lame as a result of injury. Within two to three weeks, the horses were able to walk and trot, and after two months, they were back to full health, galloping and competing.

The results also showed that the tissue within the limbs had fully recovered. Twelve months after treatment, the horses were completely fit, active and pain free.

Scientists used a combination of the vascular endothelial growth factor gene (VEGF164), to enhance blood vessel growth, and the bone morphogenetic protein 2 (BMP2), which is important for bone and cartilage development.

Both genes were derived from horses and cloned into a single plasmid DNA, which is biologically safe and unlikely to provoke an immune reaction from the body.

The research team believe this gene therapy could offer a much faster healing time, whilst significantly reducing relapse rates. Current medical therapies have a relapse rate of 60 per cent. Even the best regenerative medicine treatments have a 20 per cent relapse rate and take five or six months to work.

Lead author Professor Albert Rizvanov, from Kazan Federal University, said: “Advancing medicine, relieving pain and restoring function were the main aims of this study. We have shown that these are possible and within a much shorter time span than treatments available at the moment.”

In addition, scientists reported that no side effects or adverse reactions were seen in the horses who received treatment.

These findings not only have implications for veterinary medicine, they could also advance treatments for humans. Scientists say this type of therapy could be used in other injuries and situations, ranging from fertility problems to spinal cord injuries.

Dr Catrin Rutland, who led the work at University of Nottingham, said: “This pioneering study advances not only equine medicine but has real implications for how other species and humans are treated for lameness and other disorders in the future. The horses returned to full health after their injuries and did not have any adverse side effects. This is a very exciting medical innovation.”

The next step is to secure funding for a larger trial.

Become a member or log in to add this story to your CPD history

Defra shares new Sanitary and Phytosanitary guidance

News Story 1
 Defra has published guidance for the vet sector ahead of a proposed UK-EU Sanitary and Phytosanitary agreement.

The agreement, which will change the movement and trade of animals and related products, could see reductions in checks, paperwork and certification. As well as describing regulatory developments, the advice highlights the importance of animal ID, registration and traceability in disease control and other compliance arrangements.

The guidance can be found here. More detail is expected as negotiations progress. 

Click here for more...
News Shorts
Lords Committee opens Pet Parasite Medication inquiry

The House of Lords Environment and Climate Change Committee will launch its inquiry into Pet Parasite Medication (PPM) on Wednesday (3 June).

Focusing on treatments containing fipronil and imidacloprid, the inquiry will seek to understand distribution pathways and the impacts of PPM use and non-use on biodiversity and human health. It will also cover current regulation, monitoring, and the potential implications for pets and their owners.

The committee will hear evidence from environmental non-governmental organisations and research institutes. The public can follow the proceedings live on Parliament TV or in person in the Palace of Westminster.